thought humira biosimilar
pt
lower humira biosimilar ex-u launch mavyret hcv
spoke humira biosimilar discount
eu steeper discount trigger us lower humira
ex-u sale yr also lower hcv global market model mavyret
rev lower volum higher discount launch lost esrx/cv
formulari access lower sales/ep partli mitig
imbruvica/venclexta uptake/label expans dry-powd
transact new cfo rob michael take rein enabl seamless
transit reiter buy lower pt ep
support dcf
humira biosimilar launch eu discount rang
spoke humira ex-u biosimilar launch discount hcv global
market oncology/hematolog data readout departur
cfo in-lin abbv settlement humira biosimilar compani four
biosimilar launch certain eu market discount rang
novarti nv rate sandoz divis launch citrate-fre hyrimoz
biosimilar humira germani discount humira
rate launch citrate-fre amjevita germani discount
samsung bioepi rate /biogen rate launch
imraldi citrat discount rate hulio launch
oct assum discount upper end discount
rang sinc phase invest strategi previous shared/
reiter see note remicade/ enbrel biosimilar captur
eu market due steeper discount lower humira ex-u
sale vs street humira
us sale remain unchang settlement date-certain launch
increas confid abbv abil protect us exclus jan
expect enter market assum
enter humira patent settlement agreement boehring ingelheim
bi privat wake recent humira settlement sandoz freseniu
kabi fre-d rate addit humira ex-u adjust lower
mavyret sales/ep yr reiter buy lower pt
ep support dcf risk clinic regulatori
file orilissa launch humira intellectu properti ip risk price risk
tr target
hcv global market declin
 gilead rate two global market leader hepat viru hcv market
sept trx us hcv market show command share
respect abbv mavyret enjoy meteor rise hcv market sinc launch owe
global hcv market model assum smaller patient pool price pressur among
hcv player contribut smaller market beyond global hcv market model
patient start declin announc launch author gener
ag harvoni epclusa jan bring cost therapi also took
price cut zepati octob assum impact mrk price cut minim
zepati market share assum may need discount mavyret
price tag less competit note mavyret high share
public channel account hcv market remain commerci mavyret
rate share growth also declin recent month mavyret ad share vs
recent april express script esrx buy dave macdonald
caremark buy dave macdonald exclud mavyret formulari
mavyret strong posit public channel uptak commerci channel
domin difficult base anticip price cut commerci live coverag
limit share upsid lower mavyret us sale yoy vs street
could see addit downsid global hcv sale model
imbruvica/venclexta expans support street est
market leader hematolog two class-lead asset imbruvica venclexta
believ asset signific room growth new indic label expans
model imbruvica risk-adjust sale street imbruvica alreadi
success product approv across five differ hematolog malign clear market
leader per largest indic chronic lymphocyt leukemia/smal lymphocyt leukemia
cll/sll first-lin case us annual believ street miss continu robust
growth out-year base new use on-going clinic trial involv imbruvica
see clinicaltri gov includ announc snda imbruvica gazyva
accept prioriti review treatment first-lin cll fda action expect mid-april
 partner roch rog-ch rate also benefit roll-out venclexta
combin rituximab treatment chronic lymphocyt leukemia cll follow approv
june base murano data click note titl venclexta approv broader
r/r cll use base murano data also file venclexta aml
on-going phase program multipl myeloma add addit leg growth out-
year model venclexta global sale vs street
plenti firepow large-scal
addit organ growth hematolog anoth potenti tool off-set flattening/declin
humira/mavyret global sale out-year abbv high margin low tax rate
yield robust free cash flow gener improv abbv strong balanc sheet
net debt ebitda add consider financi flexibl model
enabl us assum aggress dividend growth rate
compound-annual-growth-rate cumul share repurchas still end net cash posit
assum announc expect pursu acquisit near-
term diversifi revenu re-stock mid-stag pipelin add/expand exist smaller therapeut
area gener help ensur meet goal top- bottom-lin growth
despit headwind humira loe declin hcv sale could pursu all-cash/
debt acquisit will bring leverag temporarili assum
gener interest acquisit rang
cfo transit seamless given deep financ bench
career abbott lab rate six spent abbv chief
offic cfo plan retir see famili reason cfo
sinc incept decemb manag financ one success
spin-off large-cap pharma histori cumul return sinc ipo dec vs
page
confid abbv deep bench financi profession make seamless
transit depart effect immedi relinquish cfo
role transit becom execut vice presid evp financ place robert michael
appoint senior vice presid cfo michael continu report
departur michael financ team sinc recent
vice presid vice-president control sinc march michael serv vice-president treasur
vice-president control commerci oper also appoint
brian durkin replac michael vice-president control durkin abt/abbv sinc serv
vice-president intern audit sinc vice-president financ divis control abbott
vision report earn nov expect
schedul meet new cfo
immunology/oncolog catalyst see exhibit
expect bi follow biosimilar manufactur sandoz freseniu settl pend global
humira patent litig near-term also expect partner johnson johnson
rate share result phoenix trial imbruvica dlbcl dec
abbv/jnj also varieti imbruvica studi on-going differ cll sub-popul young
fit patient wait watch patient etc begin read next set venclexta
catalyst includ approv aml expect end ii phase multipl myeloma
mm read-out pipelin look submit upadacitinib nda file
approval/launch assum file risankizumab psoriasi us fda
apr eu ema may assum fda/ema action abbv second replic
trial orilissa uterin fibroid elari produc posit result mid-march expect
full data two studi present medic meet data
 snda file next key catalyst rova-t result phase meru
studi sclc late
page
 sale
sg sale
impli us ex-u rang
peak sale assum biosimilar entri
oper less fx
tax rate rise next year rate lower
page
sale
sale
page
exhibit estim strh vs consensu
page
exhibit pipelin strh vs
page
exhibit in-lin product strh vs
page
late earli
late earli
late earli
file upadacitinib rheumatoid arthriti
ema approv broad r/r cll base murano data
regulatori approv expect aml patient receiv high-dos induct therapi
file us/eu pso apr base result immvent immhanc
start phase
start mm w/ mutat
data bellini r/r mm
fda deadlin releas interchang guidelin biosimilar
fda approv expect imbruvica gazyva cll/sll base data prioriti review
start axial spa gca
start see data rova-t combin opdivo/ yervoy
regulatori approv expect rheumatoid arthriti ra
taho trial second-lin small cell lung cancer sclc
meru trial first-lin small cell lung cancer sclc
page
million
sale
sale
page
million
equival
defer tax receiv
net properti equip
account payabl accru liabil
current matur lt debt
accumul comprehens incom loss
total liabil equiti
page
exhibit statement flow
million
flow oper activ
depreci amort
chang asset liabil
net cash use oper activ
flow invest activ
purchas properti equip
acquisit invest net cash acquir
decreas increas restrict cash invest
decreas increas market secur net
net cash use invest activ
flow financ activ
proce repay short-term debt
proce issuanc long-term debt
repay long-term debt net
purchas common share
proce stock option exercis
net cash flow provid financ activ
effect fx cash cash equival
net increas decreas cash cash equival
cash equival begin period
cash equival end period
page
inc highli focus research-driven biopharmaceut compani discov
develop deliv innov therapi treat health issu rang life-threaten ill
chronic condit gener total net sale sale deriv
us intern market compani core area expertis immunolog
hematology/oncolog virolog neurosci gener medicin
humira largest pharmaceut product histori biopharmaceut industri
total revenu come differ indic abbv second largest franchis hematology/
oncolog imbruvica/venclexta franchis account sale abbv
virolog franchis includ hepat product viekira/mavyret account
sale
rate buy one favorit valu name large-cap biopharmaceut
sinc launch believ time humira loss exclus us along
pipelin underappreci street thesi base humira us
exclus allow extract maximum valu franchis asset
diversifi revenu stream hematology/oncolog immunolog pipelin humira
ideal posit us volum driven growth price leverag well margin expans
think evolv legal regulatori landscap suggest us humira biosimilar competit
delay januari due long date humira patent estat global immunolog market
model assum biosimilar competit us earli legal catalyst around humira play
expect street push biosimilar entri us toward earli estim put
upward pressur street consensu humira sale estim
pipelin ideal posit view extern collabor intern
deriv asset provid next gener therapi autoimmun disord improv upon
humira best class profil posit leverag global humira infrastructur
pipelin immunolog asset includ upadacitinib select oral inhibitor risankizumab
monoclon antibodi target also posit reduc humira biosimilar risk
maxim hematology/oncolog franchis includ imbruvica venclexta hematolog
malign rova-t solid tumor
valuat risk
price target assum trade ep premium major
biopharmaceut peer group expect trade premium group settl us
patent disput humira pipelin matur multipl data read out immunolog
hematolog oncolog asset play model assum humira total sale account
sale immunolog hematology/oncolog sale new product
label expans exist asset rise sale
risk rate price target includ earlier expect humira biosimilar competit
us market addit assum compani abl gener revenu
pipelin lower humira total revenu clinic regulatori
commerci setback key pipelin asset upadacitinib risankizumab imbruvica venclexta rova-
etc could forc look extern acceler diversif sale prior humira loss
exclus us invest risk relat pharmaceut industri gener includ
continu price risk payer especi europ polit risk product develop risk
regulatori risk commerci risk legal risk patent challeng
compani mention note
rate
amgen inc rate
biogen inc rate
page
freseniu se co kgaa fre-d rate
inc rate
johnson johnson rate
 rate
novarti ag nv rate
roch hold ltd genusssch rog-ch rate
samsung biolog co ltd rate
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
